Using a PET Imaging Agent, 18F-Clofarabine (CFA), to Measure Deoxycytidine Kinase Activity in Metastatic Cancer

Inclusion Criteria

• •Histologically or cytologically proven metastatic cancer (including carcinoma, adenocarcinoma, sarcoma, or neuroendocrine cancer).
• •Subjects must have metastatic disease, confirmed by imaging, typically a CT scan of the chest/abdomen/pelvis.
• •Subjects must have measurable disease per RECIST 1.1
• •Over 18 years of age
• •ECOG performance status 0-1
• •Adequate organ function as defined by the following criteria (labs may be no more than 4 weeks prior to the screening date):
• •* Serum aspartate transaminase (AST; serum glutamic oxaloacetic transaminase \[SGOT\]) and serum alanine transaminase (ALT; serum glutamic pyruvic transaminase \[SGPT\]) \<= 2.5 x laboratory upper limit of normal (ULN)
• •* Total serum bilirubin \<= 2.0 x ULN
• •* Absolute neutrophil count (ANC) \>= 1500/uL
• •* Platelets \>= 75,000/uL
• •* Hemoglobin \>= 8.0 g/dL
• •* Serum calcium \<= 12.0 mg/dL
• •* Serum creatinine \<= 2.9 mg/dL
• •Subjects must have the ability to understand and the willingness to sign a written informed consent document
• •Patient is able to remain still for the duration of the imaging procedure (up to one hour).